LFA-1 regulated by IL-2/STAT5 pathway boosts antitumor function of intratumoral CD8⁺ T cells for improving anti-PD-1 antibody therapy.

ABSTRACT: Anti-PD-1 antibody therapy has achieved success in tumor treatment; however, the duration of its clinical benefits are typically short. The functional state of intratumoral CD8⁺ T cells substantially affects the efficacy of anti-PD-1 antibody therapy. Understanding how intratumoral CD8⁺ T cells change will contribute to the improvement in anti-PD-1 antibody therapy. In this study, we found that tumor growth was not arrested after the late administration of anti-PD-1 antibody and that the antitumor function of CD8⁺ T cells decreased with tumor progression. The results of the RNA sequencing of CD8⁺ T cells infiltrating the tumor site on days 7 and 14 showed that the cell adhesion molecule Lymphocyte Function-associated Antigen-1 (LFA-1) participate

SUBMITTER: Shan J 

PROVIDER: S-EPMC10730141 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature